INTRODUCTION AND OBJECTIVES: Prostate cancer is a major cause of death in men around the world. Despite a variety of treatments, disease progression and metastases still occur in most cases. Given the promising effect of combination with immunotherapy for prostate cancer, the construction of an immunocompetent mouse model for simultaneous monitoring of tumor volume, tumor biomarker and immune cell functions, would be useful for further understanding the mechanism of tumor progression and immune regulation.
INTRODUCTION AND OBJECTIVES: Prostate cancer is a major cause of death in men around the world. Despite a variety of treatments, disease progression and metastases still occur in most cases. Given the promising effect of combination with immunotherapy for prostate cancer, the construction of an immunocompetent mouse model for simultaneous monitoring of tumor volume, tumor biomarker and immune cell functions, would be useful for further understanding the mechanism of tumor progression and immune regulation.
METHODS: Through genetic engineering techniques, a new cell line, RM9-Luc-pIRES-KLK3 was constructed. The cells were inoculated into immunocompetent mice of strain C57BL/6 via dorsal flank, dorsolateral prostate and tail vein to obtained subcutaneous model, orthotopic model and metastasis model, respectively. Tumor volumes, non-invasive imaging and prostate-specific antigen (PSA) were evaluated. In the metastasis models, either anti-CTLA-4 antibody or PBS was administered to the tumor bearing mice, and the status of circulating immune cells was assessed by flow cytometry.
RESULTS: The new cell line, RM9-Luc-pIRES-KLK3 was successfully constructed and steadily expressed PSA and Luc, which were confirmed by Western blotting and bioluminescence detection in vitro. The level of expression was positively correlated with cell counts. Three days after injection, RM9-Luc-pIRES-KLK3 cells grew readily in the mice and the tumors could be detected by IVIS imaging system from then on. Four days later, PET scan was conducted to confirm the lesions. The intensity of bioluminescence imaging in coronal section and FDG uptake in sagittal slices of PET imaging were totally overlay. Comparing with PBS treated mice; MDSCs and T regs in peripheral blood were significantly decreased in the tumor bearing mice treated with anti-CTLA-4. Meanwhile, the proportion of CD44+CD62-effector and memory T cells on CD3+CD8+ cells were significantly increased by >2e3 times after CTLA-4 blockade compared with the control treatment, as well as IFN? and TNFa.
CONCLUSIONS: The presented models were ideally suited for real-time tracking of drug response and imaging of tumor progression and immune function. In comparison with traditional methodologies, this biomarker/imaging-based approach could lead to improved, early, and sensitive assessment of tumor status. 
PD33-12 THE ROLE OF FATTY ACID BINDING PROTEIN 4 IN PROSTATE STROMAL TUMOR MICROENVIRONMENT AND PROSTATE CANCER PROGRESSION
Mingguo Huang*, Atsushi Koizumi, Takamitsu Inoue, Shintaro Narita, Tomonori Habuchi, Akita, Japan INTRODUCTION AND OBJECTIVES: Fatty acid binding protein 4 (FABP4) is a small FA chaperone molecule. FABP4 is highly expressed in adipocytes and macrophages affect the metabolic process, but the function of FABP4 in cancer including prostate cancer (PCa) is unclear. In the present study, we investigated the expression pattern and role of FABP4 in PCa and prostate stromal cells (PrSC).
METHODS: The expression of FABP4 in PCa, PrSC and the conditioned medium were determined by the Western blotting, Immunohistochemistry and ELISA. Cytokine levels in the conditioned medium and serum was measured by the Human cytokines array kit. The metastatic and invasive PCa model was established by intraperitoneum injection of PC-3 M Luc-C6 cells into male 6-week-old Balb/c nu/nu mice, and the functional role of FABP4 was investigated.
RESULTS: FABP4 was highly expressed and secreted in the PCa PC-3 cells, and stimulated the PrSC to secretion of proinflammatory cytokine IL-8 and IL-6. PrSC augmented PCa cell invasiveness by the secretion of IL-6 and IL-8 in response to secreted FABP4 by PCa cells. In addition, FABP4 directly stimulated the PCa cell invasiveness by the upregulation of MMPs by activation of AKT and ERK signal pathways. PrSC and HFD condition increased the PCa cell invasiveness by the upregulation FABP4, IL-8 and MMPs in vivo. FABP4 was highly expressed in human PCa. The serum FABP4 levels was significantly higher in the PCa patients than normal individual (p ¼ 0.001), and the levels of FABP4 was associated with the Gleason Score (GS, p ¼ 0.018), and advanced PCa pathological T stage (pT, p ¼ 0.022).
CONCLUSIONS: FABP4 was overexpressed and secreted in the PCa, and directly stimulated the PCa progression. PrSC was activated, and augmented the PCa invasiveness by the secretion of IL-6 and IL-8 in response to secreted FABP4 by PCa cells in the prostate stromal tumor microenvironment. FABP4 may be a useful therapeutic target for prostate cancer.
